Animal Health, Nutrition & Technology USA 2022

Animal Health, Nutrition and Technology Innovation USA

Advancing Innovation to Support the Detection, Prevention and Treatment of Disease in Animals

Download Agenda
Boston, MA
21-23 June, 2022

“I had strong expectations for the conference, and they were far exceeded. The quality of the connections I made and the information learned will strengthen our company and help us succeed.”

Peter Alberti, CEO, Pet Cause Media

Why Attend

The 5th Animal Health Innovation USA is the must attend networking event in North America for innovators with new solutions to support the detection, prevention or treatment of diseases in animals.


Our mission is to showcase the most exciting investment opportunities in the sector and connect those businesses with financial investors and strategic corporate partners.


Alongside our investment pitches, we include keynote presentations and host CEO-level panel discussions that address the most pressing trends and market dynamics of the animal health, nutrition, and technology industries, across all species.

300+
Attendees
40+
Investors
80+
Start-ups
25+
Private Meetings per person

Innovation Showcase

The Innovation Showcase is returning for 2022

The showcase is a unique opportunity for emerging companies with amazing technology to present in front of the industry’s most influential figures and investors. Our finalist start-ups, hand-picked by the Selection Committee, are given the opportunity to introduce themselves, their innovations and achievements on the main stage.


This year, our presenting companies will be split into four distinguishable sections that will run across the show:

Production Animal Health

Companion Animal Health

Nutrition

Technology

Applications for 2022 have not yet opened.

Previous Speakers Include

 

Tim Bettington

Executive Vice President and President, U.S. Operations and Global Customer Experience
Zoetis

Tim Bettington is executive vice president and president, U.S. Operations and Global Customer Experience. Mr. Bettington leads our U.S. commercial operations supporting our livestock and companion animal portfolios. Additionally, he leads our Global Customer Experience function, where he leverages his extensive experience in the worldwide animal health industry.

Tim Bettington

Executive Vice President and President, U.S. Operations and Global Customer Experience
Zoetis

Tim Bettington

Executive Vice President and President, U.S. Operations and Global Customer Experience
Zoetis

Tim Bettington is executive vice president and president, U.S. Operations and Global Customer Experience. Mr. Bettington leads our U.S. commercial operations supporting our livestock and companion animal portfolios. Additionally, he leads our Global Customer Experience function, where he leverages his extensive experience in the worldwide animal health industry.

Prior to joining Zoetis in 2020, Mr. Bettington enjoyed a successful, diverse and global career in the animal health industry for more than 20 years, working in both the livestock and companion animal sectors. He joined Zoetis from Boehringer Ingelheim where he served as North American Region Head of Commercial Operations for its animal health business. In that role, Mr. Bettington had oversight for the Pet Veterinary, Pet OTC, Cattle, Swine, Equine and Poultry businesses. During his tenure at Boehringer Ingelheim and previously at Novartis Animal Health, Mr. Bettington worked in the U.S., Europe and Australia and developed a deep expertise in sales excellence, marketing, strategy and business integration.

Mr. Bettington holds a bachelor's degree in Agriculture from Western Sydney University and a master's degree in Marketing Management from the Macquarie Graduate School of Management in Sydney.

 

 

Alexandre Douzet

CEO at Pumpkin Pet Insurance & Board Member
Ollie Pets

Alexandre Douzet

CEO at Pumpkin Pet Insurance & Board Member
Ollie Pets

Alexandre Douzet

CEO at Pumpkin Pet Insurance & Board Member
Ollie Pets
 

Jared Shriver

Senior Vice President of US Cattle
Zoetis

Jared Shriver

Senior Vice President of US Cattle
Zoetis

Jared Shriver

Senior Vice President of US Cattle
Zoetis
 

François Fournier

President and CEO
Virbac North America

François Fournier

President and CEO
Virbac North America

François Fournier

President and CEO
Virbac North America
 

Julia Loew

Senior Vice President, US Pet Health Sales
Elanco

Julia Loew

Senior Vice President, US Pet Health Sales
Elanco

Julia Loew

Senior Vice President, US Pet Health Sales
Elanco
 

Tyre Grant

Sr. Director, Global Food Animal Development
Elanco

Tyre Grant

Sr. Director, Global Food Animal Development
Elanco

Tyre Grant

Sr. Director, Global Food Animal Development
Elanco
 

Bill Zollers

Head of Regulatory Affairs
Argenta

Dr. Bill Zollers, Head of Regulatory Affairs at Argenta, has extensive experience in all facets of veterinary drug development new product registrations within the US and Canada. In his 28+ years, he has led several cross-functional teams to help navigate over 20 veterinary product approvals. During this time, Dr. Zollers has held numerous positions in animal health industry trade organizations, and served on many committees, subcommittees and working groups.

 

Bill Zollers

Head of Regulatory Affairs
Argenta

Bill Zollers

Head of Regulatory Affairs
Argenta

Dr. Bill Zollers, Head of Regulatory Affairs at Argenta, has extensive experience in all facets of veterinary drug development new product registrations within the US and Canada. In his 28+ years, he has led several cross-functional teams to help navigate over 20 veterinary product approvals. During this time, Dr. Zollers has held numerous positions in animal health industry trade organizations, and served on many committees, subcommittees and working groups.

 

Dr. Zollers earned his PhD degree from the University of Missouri. He joined Argenta, a global CRO and CDMO dedicated to animal health, in February 2020 and is responsibility for oversight of regulatory consultation for drug sponsors.

 

Matthew Salois

Chief Economist and Head of Economics Division
AVMA

Matthew Salois

Chief Economist and Head of Economics Division
AVMA

Matthew Salois

Chief Economist and Head of Economics Division
AVMA
 

Matthew Rooda

CEO
SwineTech

Matthew Rooda

CEO
SwineTech

Matthew Rooda

CEO
SwineTech
 

Peter Alberti

CEO
Inulogica

Peter Alberti

CEO
Inulogica

Peter Alberti

CEO
Inulogica
 

Deb Leon

CEO
WhiskerDocs

Deb Leon

CEO
WhiskerDocs

Deb Leon

CEO
WhiskerDocs
 

Richard Hobson

CEO
Herdsy

Richard Hobson

CEO
Herdsy

Richard Hobson

CEO
Herdsy
 

Jan Robinson

Registrar & Chief Executive Officer
The College of Veterinarians of Ontario (CVO)

Jan Robinson

Registrar & Chief Executive Officer
The College of Veterinarians of Ontario (CVO)

Jan Robinson

Registrar & Chief Executive Officer
The College of Veterinarians of Ontario (CVO)
 

Jim Penrod

Executive Director
American Association of Veterinary State Board

Jim Penrod

Executive Director
American Association of Veterinary State Board

Jim Penrod

Executive Director
American Association of Veterinary State Board
 

John Butler

CEO
The Beef Marketing Group

John Butler

CEO
The Beef Marketing Group

John Butler

CEO
The Beef Marketing Group
 

Linda Rhodes

VMD, PhD, Independent and ex- CSO of Aratana Therapeutics

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Linda Rhodes

VMD, PhD, Independent and ex- CSO of Aratana Therapeutics

Linda Rhodes

VMD, PhD, Independent and ex- CSO of Aratana Therapeutics

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

 

Emily Aston, DVM, PhD

Science Advancement Manager
TechAccel LLC

Emily Aston, DVM, PhD

Science Advancement Manager
TechAccel LLC

Emily Aston, DVM, PhD

Science Advancement Manager
TechAccel LLC
 

Tom Stein

Senior Strategic Advisor
Maximus Systems

Tom Stein

Senior Strategic Advisor
Maximus Systems

Tom Stein

Senior Strategic Advisor
Maximus Systems
 

Phil Hord

Director, Research & Innovation
Hord Family Farms

Phil Hord

Director, Research & Innovation
Hord Family Farms

Phil Hord

Director, Research & Innovation
Hord Family Farms
 

Jack A Bobo

Futurist
Keynote Speaker

Jack A Bobo

Futurist
Keynote Speaker

Jack A Bobo

Futurist
Keynote Speaker
 

Todd B. Richter C.F.A

Senior Managing Director, Global Healthcare Investment Banking Group
Guggenheim Partners

Todd Richter is currently a Senior Managing Director at Guggenheim Partners. His primary focus is on the healthcare services field including managed care/payer services, physician-related businesses and all forms of distribution and outsourcing. In addition, Mr. Richter is responsible for Guggenheim Partners’ coverage of the global animal health field. From 2016 until 2018 Mr. Richter was Vice Chairman of Global Banking at Barclays.

Todd B. Richter C.F.A

Senior Managing Director, Global Healthcare Investment Banking Group
Guggenheim Partners

Todd B. Richter C.F.A

Senior Managing Director, Global Healthcare Investment Banking Group
Guggenheim Partners

Todd Richter is currently a Senior Managing Director at Guggenheim Partners. His primary focus is on the healthcare services field including managed care/payer services, physician-related businesses and all forms of distribution and outsourcing. In addition, Mr. Richter is responsible for Guggenheim Partners’ coverage of the global animal health field. From 2016 until 2018 Mr. Richter was Vice Chairman of Global Banking at Barclays. From 1999 to 2016 Todd Richter was a Senior Managing Director in the Global Healthcare Corporate & Investment Banking Group at Bank of America Merrill Lynch. From 1981 to 1999, Mr. Richter served as the head of the healthcare services analytical team for Morgan Stanley. Todd Richter earned a B.B.A. in Finance from the College of William & Mary in 1979 and an M.B.A. in Finance with Honors from Indiana University in 1981. Todd was recognized 16 times as a member of the Institutional Investor’s All-America Research Team. He was also listed many times among the Wall Street Journal’s “All-Star” analysts and on the Reuters research poll. Mr. Richter is currently a member of the Board of Directors (Vice Chairman) of Bideawee, one of the nation’s leading animal rescue organizations; a member of the Board of Directors at the Stratton Mountain School (SMS) in Stratton, Vermont, a member of the Board of Directors at Animal Lighthouse Rescue (ALR), and a member of the Dean’s Council for the Kelley School of Business at Indiana University.  Finally Mr. Richter is on the Board and faculty of the Columbia University Mailman School of Public Health teaching a course on healthcare consolidation to MPH and MHA candidates. 

 

John Richeson

Associate Professor of Animal Science
West Texas A&M

Dr. John Richeson is currently an Associate Professor of Animal Science and faculty supervisor of the Research Feedlot at West Texas A&M University. He teaches several undergraduate and graduate courses, serves on numerous University and professional committees, and is an advisory board member of four different industry organizations. Dr. Richeson received his BS, MS, and PhD in Animal Science from Oklahoma State University (2000), Texas Tech University (2004), and University of Arkansas (2011), respectively.

John Richeson

Associate Professor of Animal Science
West Texas A&M

John Richeson

Associate Professor of Animal Science
West Texas A&M

Dr. John Richeson is currently an Associate Professor of Animal Science and faculty supervisor of the Research Feedlot at West Texas A&M University. He teaches several undergraduate and graduate courses, serves on numerous University and professional committees, and is an advisory board member of four different industry organizations. Dr. Richeson received his BS, MS, and PhD in Animal Science from Oklahoma State University (2000), Texas Tech University (2004), and University of Arkansas (2011), respectively. Research interests include evaluating management, nutritional, and immunological manipulations to improve health and growth of stocker and feedlot cattle. Additional research efforts have focused on evaluation of biomarker and behavior technology to assist in the prediction and early detection of bovine respiratory disease.

 

 

Cynthia Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

Cynthia Cole

Partner
Digitalis Ventures

Cynthia Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

 

Michael Rohlfsen

Chief Commercial Officer
TechAccel, LLC

Michael Rohlfsen

Chief Commercial Officer
TechAccel, LLC

Michael Rohlfsen

Chief Commercial Officer
TechAccel, LLC
 

George Heidgerken

Animal Health and Agribusiness Expert

George Heidgerken

Animal Health and Agribusiness Expert

George Heidgerken

Animal Health and Agribusiness Expert
 

Sarai Kemp

VP Business Development
Trendlines Agrifood

As VP Business Development for Trendlines Agrifood (Israel) since 2012 and VP Deal Flow for the Trendlines Agrifood Fund (Singapore), Sarai Kemp is responsible for sourcing start-ups, evaluating opportunities, negotiating, and closing investments and working with portfolio companies post-investment. Sarai is a board member on Hargol FoodTech, AgroScout, FruitSpec and AlgaHealth.

Sarai Kemp

VP Business Development
Trendlines Agrifood

Sarai Kemp

VP Business Development
Trendlines Agrifood

As VP Business Development for Trendlines Agrifood (Israel) since 2012 and VP Deal Flow for the Trendlines Agrifood Fund (Singapore), Sarai Kemp is responsible for sourcing start-ups, evaluating opportunities, negotiating, and closing investments and working with portfolio companies post-investment. Sarai is a board member on Hargol FoodTech, AgroScout, FruitSpec and AlgaHealth.

Sarai brings more than 20 years’ experience in agricultural, consumer goods, and high-tech industries, including in sales, marketing, and business development for international companies such as Afimilk and Keter Plastic. She has worked intensively with companies in East Asia.

Sarai received an MBA from Haifa University and a B.A. from Tel Aviv University.

 

Lowell Ackerman

Veterinary Specialist Consultant & Lecturer

Lowell Ackerman

Veterinary Specialist Consultant & Lecturer

Lowell Ackerman

Veterinary Specialist Consultant & Lecturer
 

Duane Cantrell

Managing Partner
Fulcrum Global Capital




Duane Cantrell

Managing Partner
Fulcrum Global Capital

Duane Cantrell

Managing Partner
Fulcrum Global Capital




 

Tom Overbay

Partner
Expedite Animal Health

Tom Overbay

Partner
Expedite Animal Health

Tom Overbay

Partner
Expedite Animal Health
 

Lesley C. Rausch-Derra

Principal
Right Direction Animal Health Consulting

Lesley C. Rausch-Derra

Principal
Right Direction Animal Health Consulting

Lesley C. Rausch-Derra

Principal
Right Direction Animal Health Consulting
 

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

2021 Partners

Previous Partners

Previous Media Partners

Register Your Interest

Register Your Interest In The Event Here

Be the first to receive the 2022 agenda! Simply fill in your details below and we will send you the agenda as soon as it’s released

 

REGISTER YOUR INTEREST

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...
Payment Terms for Animal Health Investment Europe:
  • Please note that a $70 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in USD
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
  • Please Note: No additional discounts are available on ‘Emerging Company’ pricing.

Terms & Conditions

In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.

Global Advisory Board

Author:

Glenn David

Executive Vice President and Group President, International Operations
Zoetis Inc.

Author:

Laurent Genet

Chief Strategy Officer
Nutreco

Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.

Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management. 

With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.

Author:

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Author:

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.

Author:

Jean-Luc Michel

Senior Vice President, Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Author:

Kathy V. Turner

Corporate Vice President and Global Chief Marketing Officer
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

Author:

Tom Zerzan

President, Companion Animal
Phibro

Author:

Linda Rhodes

VMD, PhD, Independent and ex- CSO of Aratana Therapeutics

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Author:

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Author:

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Selection Committee

Author:

Charles Hoare

Managing Director, Head of European Healthcare M&A
Stifel

Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.

He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.

Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.

Author:

Matthias Hofer

Managing Partner
Stonehaven Consulting Group

Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.

Author:

Julia Stephanus

Partner
Borealis Ventures

Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry.  Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups. 

Julia has been involved in the development and launch of 28 veterinary products.  She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.

As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.

As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010.  A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.      

Author:

Claire Smith

Biotech VC
Anterra Capital

Claire is an Associate at Anterra Capital. Prior to joining Anterra, she was the Chief of Staff at Crestovo, a biotech start-up developing microbiome-based therapies for infectious diseases. Before that, she worked as a consultant at ClearView Healthcare Partners, where she advised pharmaceutical and biotech clients on a variety of growth strategy topics. She graduated from the Massachusetts Institute of Technology with Bachelor of Science degrees in biological engineering and management science.

Author:

Cynthia Cole

Partner
Digitalis Ventures

Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.

Author:

Dino Dedic, CFA

Senior Managing Director
Guggenheim Partners

Author:

Paul Dick

President
Paul Dick & Associates Ltd and Managing Partner, Vet Venture Capital Inc.

Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.

While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.

His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.

Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.

In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).

Author:

Duane Cantrell

Managing Partner
Fulcrum Global Capital




Author:

Laëtitia Gerbe

Partner for Investments for AVF Fund
Seventure Partners

Author:

Yorán Meijers

Food Agriculture VC
Anterra Capital

Yorán is an Analyst at Anterra Capital. He is primarily responsible for deal sourcing and execution with a focus on digital technologies. He is also involved in portfolio management.

Prior to joining Anterra, Yorán was active as a researcher in the Creative Machines Lab at Columbia University, focused on developing novel cooking techniques for 3D food printing applications. Before that, he has worked at the process technology department at Heinz and the product and process development department at Cargill.

Yorán holds a MSc in Sustainable Food Process Engineering and a BSc in Food Technology from Wageningen University with a BSc minor in Food Business and Management from UC Davis.

Author:

Benjamin Shaw

Partner
Borealis Ventures

Author:

Nicky Deasy

Managing Partner
The Yield Lab Europe

Author:

Barry Brackner

Seasoned Board Director & Senior Leader

Barry is a strategy consultant to the pharma, welfare, retail, tech and veterinary profession having previously held senior executive roles within the veterinary profession most recently an executive board role at CVS s Marketing and Commercial Director, the largest PLC veterinary group in Europe, a role which involved him developing and delivering marketing strategies for the organisation and its member practices and honing its commercial operations. This role saw him supporting growth and the integration of over 300 veterinary practices, crematoria, out of hours clinics and multi-disciplinary hospitals and bringing to market a number of own label prescription and non-prescription products.

Author:

Sébastien Lafon

Founder
Adapt1st LLC

Author:

Eli Hasson

Founding Partner
PHIL Ventures

Author:

Matthieu Vermersch

VVNP's Founder & Managing Partner
VisVires New Protein Capital

Become a Partner

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920, email Simon Pickles at [email protected] or downloading our agenda and clicking the "Interested in Sponsorship" box below.

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

Other events you might be interested in:

Animal Health LatAm 2021

Animal Health Asia 2021

Animal Health, Nutrition and Technology Innovation Europe 2022